---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-057132"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2023-07-14T23:59:59+00:00"
generated_at: "2026-06-13T08:27:55.080537+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics closes $7.5 million private placement of common stock and warrants

## Summary
- Closed offering of 4,285,715 shares (or pre-funded warrants) at $1.75 per share, raising ~$7.5M gross.
- Issued warrants to purchase 4,285,715 shares at $1.75, exercisable for 5.5 years from issuance.
- Net proceeds to be used for working capital to advance tecarfarin development.
- Directors and officers subject to 60-day lock-up after registration statement effectiveness.
- Placement agent H.C. Wainwright; Boustead Securities acted as financial advisor.

## SEC filing metadata
- accession: 0001213900-23-057132
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2023-07-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390023057132/0001213900-23-057132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390023057132/ea181825-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-057132
- JSON: https://secwatch.observer/filing/0001213900-23-057132.json
- Plain text: https://secwatch.observer/filing/0001213900-23-057132.txt

## Key facts
- Material Agreements
  Cadrenal Therapeutics, Inc. entered into Engagement Agreement with H.C. Wainwright & Co., LLC (effective 2023-07-12).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: H.C. Wainwright & Co., LLC
  - Effective: 2023-07-12
  source text: Pursuant to a letter agreement dated July 12, 2023 (the “Engagement Agreement”), H.C. Wainwright & Co., LLC (“HWC”) acted as placement agent for the Private Placement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390023057132/0001213900-23-057132-index.htm
- Material Agreements
  Cadrenal Therapeutics, Inc. entered into Registration Rights Agreement with the Investor (effective 2023-07-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the Investor
  - Effective: 2023-07-12
  source text: In connection with the Private Placement, the Company has entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investor, dated July 12, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390023057132/0001213900-23-057132-index.htm
- Material Agreements
  Cadrenal Therapeutics, Inc. entered into Purchase Agreement with an institutional accredited investor valued at approximately $7.5 million (effective 2023-07-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an institutional accredited investor
  - Value: approximately $7.5 million
  - Effective: 2023-07-12
  source text: On July 12, 2023, Cadrenal Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional accredited investor (the “Investor”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390023057132/0001213900-23-057132-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.